

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

DR. REDDY'S LABORATORIES, INC.  
and  
DR. REDDY'S LABORATORIES, LTD.,

Petitioners,

v.

NOVO NORDISK A/S,  
Patent Owner

U.S. Patent No. 10,335,462 to Jensen  
Issue Date: July 2, 2019  
Title: Use Of Long-Acting Glp-1 Peptides

---

*Inter Partes* Review No. IPR2024-00009  
U.S. Patent No. 10,335,462

---

**PETITIONER UPDATED EXHIBIT LIST**  
(As of March 29, 2024)

## UPDATED EXHIBIT LIST

EXHIBIT	DESCRIPTION
1001	U.S. Patent No. 10,335,462
1002	Prosecution history excerpts for U.S. Patent No. 10,335,462
1003	Declaration of John Bantle, MD
1004	CV of John Bantle, MD
1005	Declaration of William J. Jusko, Ph.D.
1006	CV of William J. Jusko, Ph.D.
1007	Declaration of Paul Dalby, Ph.D.
1008	CV of Paul Dalby, Ph.D.
1009	Intentionally Left Blank
1010	Intentionally Left Blank
1011	WO 2011/138421
1012	Lovshin, <i>Incretin-Based Therapies for Type 2 Diabetes Mellitus</i> , 5 NATURE REV. ENDOCRINOLOGY 262 (2009)
1013	Clinical Trial No. NCT00696657
1014	Clinical Trial No. NCT00851773
1015	WO 2006/097537
1016	U.S. Patent Application Pub. No. US2007/0010424
1017	U.S. Patent No. 5,512,549
1018	Banting, <i>The Internal Secretion of the Pancreas</i> , 7 J. LAB. CLINICAL MED. 251 (1922)
1019	Bell, <i>Hamster Preproglucagon Contains the Sequence of Glucagon and Two Related Peptides</i> , 302 NATURE 716 (1983)

EXHIBIT	DESCRIPTION
1020	Bydureon prescribing information (Jan. 2012)
1021	Byetta prescribing information (Oct. 2009)
1022	Drab, <i>Incretin-Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects</i> , 30 PHARMACOTHERAPY 609 (2010)
1023	Drucker, <i>Enhancing Incretin Action for the Treatment of Type 2 Diabetes</i> , 26 DIABETES CARE 2929 (2003)
1024	Drucker, <i>The Incretin System: Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes</i> , 368 LANCET 1696 (2006)
1025	Glaesner, <i>Engineering and Characterization of the Long-Acting Glucagon-Like Peptide-1 Analogue LY2189265, an Fc Fusion Protein</i> , 26 DIABETES/METABOLISM RSCH. & REV. 287 (2010)
1026	HARRISON'S PRINCIPLES OF INTERNAL MED., Chapter 338 (Fauci et al. eds. 17th ed. 2008)
1027	Holst, <i>Truncated Glucagon-like Peptide I, an Insulin-Releasing Hormone from the Distal Gut</i> , 211 (2) FEBS LETTERS 169 (1987)
1028	Holst, <i>Glucagon-Like Peptide 1 and Inhibitors of Dipeptidyl Peptidase IV in the Treatment of Type 2 Diabetes Mellitus</i> , 4 CURRENT OP. IN PHARMACOLOGY 589 (2004)
1029	Jimenez-Solem, <i>Dulaglutide, a Long-Acting GLP-1 Analog Fused with an Fc Antibody Fragment for the Potential Treatment of Type 2 Diabetes</i> , 12 CURRENT OP. IN MOLECULAR THERAPEUTICS 790 (2010)
1030	Kim, <i>Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects with Type 2 Diabetes</i> , 30 DIABETES CARE 1487 (2007)

EXHIBIT	DESCRIPTION
1031	Knudsen, <i>GLP-1 Derivatives as Novel Compounds for the Treatment of Type 2 Diabetes: Selection of NN2211 for Clinical Development</i> , 26 DRUGS OF THE FUTURE 677 (2001)
1032	Knudsen, <i>Glucagon-like Peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes</i> , 47 J. MED. CHEMISTRY 4128 (2004)
1033	Knudsen, <i>Liraglutide, a GLP-1 Analogue to Treat Diabetes</i> , in ANALOGUE-BASED DRUG DISCOVERY II (Fischer & Ganellin eds. 2010)
1034	U.S. Patent No. 6,268,343 (“Knudsen patent”)
1035	Lund, <i>Emerging GLP-1 Receptor Agonists</i> , 16 EXPERT OP. ON EMERGING DRUGS 607 (2011)
1036	Mojsov, <i>Insulintropin: Glucagon-like Peptide I (7-37) Co- encoded in the Glucagon Gene is a Potent Simulator of Insulin Release in the Perfused Rat Pancreas</i> , 79 J. CLINICAL INVESTIGATION 616 (1987)
1037	Nielsen, <i>Pharmacology of Exenatide (Synthetic Exendin-4): A Potential Therapeutic for Improved Glycemic Control of Type 2 Diabetes</i> , 117 REGUL. PEPTIDES 77 (2004)
1038	Seino, <i>Dose-Dependent Improvement in Glycemia with Once-Daily Liraglutide without Hypoglycemia or Weight Gain: A Double-Blind, Randomized, Controlled Trial in Japanese Patients with Type 2 Diabetes</i> , 81 DIABETES RSCH. & CLINICAL PRACTICE 161 (2008)
1039	Victoza, PHYSICIANS’ DESK REFERENCE (65th ed. 2010)
1040	Vilsbøll, <i>Glucagon-Like Peptide-1 and Diabetes Treatment</i> , 21 INT’L DIABETES MONITOR 1 (2009)
1041	WO 03/002136
1042	WO 91/11457

EXHIBIT	DESCRIPTION
1043	U.S. Patent App. Pub. 2004/0102486
1044	Rohatagi, <i>Model-Based Development of a PPAR<math>\gamma</math> Agonist, Rivoglitazone, to Aid Dose Selection and Optimize Clinical Trial Designs</i> , 48 J. CLINICAL PHARMACOLOGY 1420 (2008)
1045	Shargel, APPLIED BIOPHARMACEUTICS & PHARMACOKINETICS (5th ed. 2005)
1046	Yun, <i>Pharmacokinetic and Pharmacodynamic Modelling of the Effects of Glimepiride on Insulin Secretion and Glucose Lowering in Healthy Humans</i> , 31 J. CLINICAL PHARMACY & THERAPEUTICS 469 (2006)
1047	Tamimi, <i>Drug Development: From Concept to Marketing!</i> , 113 NEPHRON CLINICAL PRACTICE c125 (2009)
1048	FDA Guidance for Industry, <i>Exposure-Response Relationships - Study Design, Data, Analysis, and Regulatory Applications</i> (Apr. 2003)
1049	International Conference on Harmonisation; <i>Dose-Response Information to Support Drug Registration; Guideline; Availability</i> , 59 Fed. Reg. 55972 (Nov. 9, 1994) (“ICH 1994”)
1050	Garber, <i>Efficacy of Metformin in Type II Diabetes: Results of a Double-Blind, Placebo-Controlled, Dose-Response Trial</i> , 102 AM. J. MED. 491 (1997)
1051	Landersdorfer, <i>Pharmacokinetic/Pharmacodynamic Modelling in Diabetes Mellitus</i> , 47(7) CLINICAL PHARMACOKINETICS 417 (2008)
1052	Madsbad, <i>An Overview of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists—Available Efficacy and Safety Data and Perspectives for the Future</i> , 13 DIABETES, OBESITY & METABOLISM 394 (2011)
1053	Møller, <i>Mechanism-Based Population Modelling for Assessment of L-Cell Function Based on Total GLP-1 Response Following an Oral</i>

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.